Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant

Immunopharmacology and Immunotoxicology

Volumn 33, Issue 1, 2011, Pages 211-219

  Li, Na ^a   Yu, Yun Zhou ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

adjuvant; botulinum neurotoxin; DNA vaccine; GM CSF; immunogenicity

Indexed keywords

BACTERIAL VACCINE; BOTULINUM TOXIN A; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CLOSTRIDIUM BOTULINUM; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BOTULINUM TOXINS, TYPE A; BOTULISM; CLOSTRIDIUM BOTULINUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; PLASMIDS; REPLICON; SEMLIKI FOREST VIRUS; VACCINES, DNA;

CLOSTRIDIUM BOTULINUM; MUS; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 79551595130     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923971003782327     Document Type: Article

References (41)

1. Schiavo, G., Matteoli, M., Montecucco, C. Neurotoxins afecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-66.
2. Turton, K., Chaddock, J.A., Acharya, K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552-8.
3. Byrne, M.P., Smith, L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82, 955-66.
4. Middlebrook, J.L. Production of vaccines against leading biowar-fare toxins can utilize DNA scientifc technology. Adv. Drug Deliv. Rev. 2005, 57, 1415-23.
5. Smith, L.A., Rusnak, J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 2007, 27, 303-18.
6. Clayton, M.A., Clayton, J.M., Brown, D.R., Middlebrook, J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995, 63, 2738-42.
7. Smith, L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998, 36, 1539-48.
8. Holley, J.L., Elmore, M., Mauchline, M., Minton, N., Titball, R.W. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000, 19, 288-97.
9. Tavallaie, M., Chenal, A., Gillet, D., Pereira, Y., Manich, M., Gibert, M., Rafestin, S., Popof, M.R., Marvaud, J.C. Interaction between the two subdomains of the C-terminal part of the botu-linum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 2004, 572, 299-306.
10. Baldwin, M.R., Tepp, W.H., Pier, C.L., Bradshaw, M., Ho, M., Wilson, B.A., Fritz, R.B., Johnson, E.A., Barbieri, J.T. Characterization of the antibody response to the receptor binding domain of botu-linum neurotoxin serotypes A and E. Infect. Immun. 2005, 73, 6998-7005.
11. Ravichandran, E., Al-Saleem, F.H., Ancharski, D.M., Elias, M.D., Singh, A.K., Shamim, M., Gong, Y., Simpson, L.L. Trivalent vac-cine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 2007, 75, 3043-54.
12. Baldwin, M.R., Tepp, W.H., Przedpelski, A., Pier, C.L., Bradshaw, M., Johnson, E.A., Barbieri, J.T. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 2008, 76, 1314-8.
13. Yu, Y.Z., Li, N., Zhu, H.Q., Wang, R.L., Du, Y., Wang, S., Yu, WY., Sun, Z.W. Te recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an efective botulism vaccine candidate. Vaccine 2009, 27, 2816-22.
14. Yu, YZ, Sun, ZW, Li, N, Wang, S, Yu, WY. Protection with a recombinant Hc of Clostridium botulinum neurotoxin sero-type A from Escherichia coli as an efective subunit vaccine. Immunopharmacol Immunotoxicol. 2008, 31, 261-266.
15. Yu, Y.Z., Li, N., Wang, R.L., Zhu, H.Q., Wang, S., Yu, WY., Sun, Z.W. Evaluation of a recombinant Hc of Clostridium botu-linum neurotoxin serotype F as an efective subunit vaccine. Clin. Vaccine Immunol. 2008, 15, 1819-23.
16. Jennifer, Clayton, John, L, Middlebrook. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin sero-type A. Vaccine. 2000, 18, 1855-62.
17. Shyu, R.H., Shaio, M.F., Tang, S.S., Shyu, H.F., Lee, C.F., Tsai, M.H., Smith, J.E., Huang, H.H., Wey, J.J., Huang, J.L., Chang, H.H. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J. Biomed. Sci. 2000, 7, 51-7.
18. Bennett, A.M., Perkins, S.D., Holley, J.L. DNA vaccination pro-tects against botulinum neurotoxin type F. Vaccine 2003, 21, 3110-7.
19. Jathoul, A.P., Holley, J.L., Garmory, H.S. Efcacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using difer-ent promoters. Vaccine 2004, 22, 3942-6.
20. Lee, J.S., Pushko, P., Parker, M.D., Dertzbaugh, M.T., Smith, L.A., Smith, J.F. Candidate vaccine against botulinum neurotoxin sero-type A derived from a Venezuelan equine encephalitis virus vec-tor system. Infect. Immun. 2001, 69, 5709-15.
21. Lee, J.S., Groebner, J.L., Hadjipanayis, A.G., Negley, D.L., Schmaljohn, A.L., Welkos, S.L., Smith, L.A., Smith, J.F. Multiagent vaccines vectored by Venezuelan equine encephalitis virus rep-licon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006, 24, 6886-92.
22. Yu, YZ., Zhang, S.M., Sun, Z.W., Wang, S., Yu, WY. Enhanced immune responses using plasmid DNA replicon vaccine encod-ing the Hc domain of Clostridium botulinum neurotoxin sero-type A. Vaccine 2007, 25, 8843-50.
23. Yu, YZ., Li, N., Wang, S., Yu, W.Y., Sun, Z.W. Improved immu-nogenicity and protective efcacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting. Immunopharmacol. Immunotoxicol. 2009, 31, 397-404.
24. Yu, YZ, Jiyu, Yu, Li, N, Wang, RL, Wang, S, Yu, WY, Sun, ZW. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine. 2009, 27, 6148-6153.
25. Otten, G.R., Schaefer, M., Doe, B., Liu, H., Srivastava, I., Megede, J., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., Montefori, D., Lewis, M., Driver, D.A., Dubensky, T., Polo, J.M., Donnelly, J., O'Hagan, D.T., Barnett, S., Ulmer, J.B. Enhanced potency of plas-mid DNA microparticle human immunodefciency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J. Virol. 2005, 79, 8189-200.
26. Ramakrishna, L., Anand, K.K., Mohankumar, K.M., Ranga, U. Codon optimization of the tat antigen of human immunodef-ciency virus type 1 generates strong immune responses in mice following genetic immunization. J. Virol. 2004, 78, 9174-89.
27. Tomas, L.J., Hammond, R.A., Forsberg, E.M., Geoghegan-Barek, K.M., Karalius, B.H., Marsh, H.C. Jr, Rittershaus, C.W. Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum. Vaccin. 2009, 5, 79-84.
28. Kutzler, M.A., Robinson, T.M., Chattergoon, M.A., Choo, D.K., Choo, AY., Choe, PY., Ramanathan, M.P., Parkinson, R., Kudchodkar, S., Tamura, Y., Sidhu, M., Roopchand, V, Kim, JJ., Pavlakis, G.N., Felber, B.K., Waldmann, T.A., Boyer, J.D., Weiner, D.B. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J. Immunol. 2005, 175, 112-23.
29. Sedegah, M., Charoenvit, Y., Aguiar, J., Sacci, J., Hedstrom, R., Kumar, S., Belmonte, A., Lanar, D.E., Jones, T.R., Abot, E., Druilhe, P., Corradin, G., Epstein, J.E., Richie, T.L., Carucci, D.J., Hofman, S.L. Efect on antibody and T-cell responses of mix-ing fve GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun. 2004, 5, 553-61.
30. Sumida, S.M., McKay, P.F., Truitt, D.M., Kishko, M.G., Arthur, J.C., Seaman, M.S., Jackson, S.S., Gorgone, D.A., Lifton, M.A., Letvin, N.L., Barouch, D.H. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Invest. 2004, 114, 1334-42.
31. Toubaji, A., Hill, S., Terabe, M., Qian, J., Floyd, T., Simpson, R.M., Berzofsky, J.A., Khleif, S.N. Te combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vac-cines and provides long term tumor protection. Vaccine 2007, 25, 5882-91.
32. Yoon, H.A., Aleyas, A.G., George, J.A., Park, S.O., Han, Y.W., Lee, J.H., Cho, J.G., Eo, S.K. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol. Immunol. 2006, 50, 83-92.
33. Chu, Y., Xia, M., Lin, Y., Li, A., Wang, Y., Liu, R., Xiong, S. T2-dominated antitumor immunity induced by DNA immuniza-tion with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ter. 2006, 13, 510-9.
34. Perales, M.A., Yuan, J., Powel, S., Gallardo, H.F., Rasalan, T.S., Gonzalez, C, Manukian, G., Wang, J., Zhang, Y., Chapman, P.B., Krown, S.E., Livingston, P.O., Ejadi, S., Panageas, K.S., Engelhorn, M.E., Terzulli, S.L., Houghton, A.N., Wolchok, J.D. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol. Ter. 2008, 16, 2022-9.
35. Reali, E., Canter, D., Zeytin, H., Schlom, J., Greiner, J.W. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with diferent vaccine platforms. Vaccine 2005, 23, 2909-21.
36. Tenbusch, M., Kuate, S., Tippler, B., Gerlach, N., Schimmer, S., Dittmer, U., Uberla, K. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol. 2008, 9, 13.
37. Sun, X., Hodge, L.M., Jones, H.P., Tabor, L., Simecka, J.W. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 2002, 20, 1466-74.
38. Zhang, X., Divangahi, M., Ngai, P., Santosuosso, M., Millar, J., Zganiacz, A., Wang, J., Bramson, J., Xing, Z. Intramuscular immu-nization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 2007, 25, 1342-52.
39. Kwissa, M., Lindblad, E.B., Schirmbeck, R., Reimann, J. Codelivery of a DNA vaccine and a protein vaccine with alumi-num phosphate stimulates a potent and multivalent immune response. J. Mol. Med. 2003, 81, 502-10.
40. Ulmer, J.B., DeWitt, C.M., Chastain, M., Friedman, A., Donnelly, JJ., McClements, W.L., Caulfeld, MJ., Bohannon, K.E., Volkin, D.B., Evans, R.K. Enhancement of DNA vaccine potency using conven-tional aluminum adjuvants. Vaccine 1999, 18, 18-28.
41. Wang, S., Liu, X., Fisher, K., Smith, J.G., Chen, F., Tobery, T.W., Ulmer, J.B., Evans, R.K., Caulfeld, MJ. Enhanced type I immune response to a hepatitis B DNA vaccine by formula-tion with calcium-or aluminum phosphate. Vaccine 2000, 18, 1227-35.